生物大动脉置换后将华法林与阿司匹林进行比较:一项前性研究
Tiziano Gherli1, Andrea Colli, Claudio Fragnito
1Department of Cardiac Surgery, University of Parma, Parma, Italy.
Circulation
|August 4, 2004
概括
华法林早期抗凝剂在生物大动脉置换 (BAVR) 后的患者中与阿司匹林相比没有显著的优势. 这项研究发现,两种抗血栓疗法之间的脑缺血事件,出血和生存率相似.
科学领域:
- 心血管外科心血管外科
- 血栓形成和血液静止.
- 临床药理学 临床药理学
背景情况:
- 带有假心脏门的患者面临门血栓形成和动脉血栓栓塞的风险增加.
- 在生物主动脉置换 (BAVR) 后的术后抗血栓治疗仍然存在争议.
- 目前的指导方针在术后早期使用华法林时提出了相互矛盾的建议.
研究的目的:
- 在接受BAVR的患者中,比较术后华法林与阿司匹林的疗效.
- 为了评估脑缺血事件,出血和早期术后期生存率.
主要方法:
- 这是一项前性研究,涉及249名在2001年至2002年期间接受BAVR的患者.
- 患者接受了华法林治疗3个月 (141名患者) 或仅服用阿司匹林 (108名患者).
- 关键的终点包括脑缺血事件,严重出血和生存率.
主要成果:
- 手术后24小时至3个月间脑缺血事件发生率没有显著差异.
- 华法林和阿司匹林组之间的重大出血事件的发生率相似.
- 在无中风生存率或整体生存率上没有统计学上显著的差异.
结论:
- 在BAVR患者中,使用华法林的早期抗凝剂似乎没有比低剂量阿司匹林治疗方案提供优势.
- 目前的证据不支持华法林在这个患者群体中比阿司匹林更有效.
- 可能需要进一步的研究来澄清最佳的抗血栓策略.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
